Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

Sam K. Bouchillon, Jonathan R. Iredell, Timothy Barkham, Kyungwon Lee, Michael J. Dowzicky

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalInternational Journal of Antimicrobial Agents
Volume33
Issue number2
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Enterococcus faecium
Acinetobacter
Klebsiella pneumoniae
Staphylococcus aureus
Escherichia coli
Enterobacter
Serratia marcescens
Methicillin
Microbial Sensitivity Tests
Vancomycin
Bacteria
tigecycline
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{09202123588442d2b24f1fbdac8d1db6,
title = "Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)",
abstract = "As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2{\%} of Acinetobacter spp. were multidrug-resistant, and 17.0{\%} of Klebsiella pneumoniae and 10.6{\%} of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5{\%} of Staphylococcus aureus were meticillin-resistant and 21.7{\%} of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90{\%} of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.",
author = "Bouchillon, {Sam K.} and Iredell, {Jonathan R.} and Timothy Barkham and Kyungwon Lee and Dowzicky, {Michael J.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.ijantimicag.2008.07.031",
language = "English",
volume = "33",
pages = "130--136",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

AU - Bouchillon, Sam K.

AU - Iredell, Jonathan R.

AU - Barkham, Timothy

AU - Lee, Kyungwon

AU - Dowzicky, Michael J.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

AB - As part of the Tigecycline Evaluation and Surveillance Trial (TEST), Gram-negative and Gram-positive organisms were collected from 31 medical centres in nine countries in the Asia-Pacific Rim between 2004 and 2007. Overall, 34.2% of Acinetobacter spp. were multidrug-resistant, and 17.0% of Klebsiella pneumoniae and 10.6% of Escherichia coli produced extended-spectrum β-lactamases. A total of 39.5% of Staphylococcus aureus were meticillin-resistant and 21.7% of Enterococcus faecium were vancomycin-resistant. Tigecycline MIC90 values (minimum inhibitory concentration for 90% of the organisms) were ≤2 mg/L against Acinetobacter spp., K. pneumoniae, E. coli, Enterobacter spp. and Serratia marcescens and ≤0.25 mg/L against S. aureus, E. faecalis and Enterococcus faecium. Antimicrobial resistance is widespread in the Asia-Pacific Rim. Tigecycline has excellent in vitro activity against a broad spectrum of bacteria, including resistant strains.

UR - http://www.scopus.com/inward/record.url?scp=58149185269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149185269&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2008.07.031

DO - 10.1016/j.ijantimicag.2008.07.031

M3 - Article

VL - 33

SP - 130

EP - 136

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -